<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="/sitemap.xsl"?>
<!--Generated by the Simple XML Sitemap Drupal module: https://drupal.org/project/simple_sitemap.-->
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
 <url>
  <loc>https://investor.bridgebio.com/</loc>
  <lastmod>2025-01-31T16:34:49-05:00</lastmod>
  <changefreq>daily</changefreq>
  <priority>1.0</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/committee-details/audit-committee</loc>
  <lastmod>2022-01-11T14:46:38-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/committee-details/nominating-governance-committee</loc>
  <lastmod>2023-05-01T18:47:21-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/committee-details/compensation-committee</loc>
  <lastmod>2023-05-01T18:49:24-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bridgebio-pharma-inc-rd-day</loc>
  <lastmod>2021-02-17T13:25:03-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/10th-annual-svb-leerink-global-healthcare-conference</loc>
  <lastmod>2021-06-09T09:53:41-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/hc-wainwright-global-life-sciences-conference</loc>
  <lastmod>2021-06-09T09:53:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bridgebio-pharma-discuss-proof-concept-data-encaleret-autosomal-dominant</loc>
  <lastmod>2021-03-22T07:51:26-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/2021-global-healthcare-virtual-conference</loc>
  <lastmod>2021-05-25T11:50:22-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/2021-jefferies-virtual-healthcare-conference</loc>
  <lastmod>2021-05-26T11:40:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/goldman-sachs-42nd-annual-global-healthcare-conference</loc>
  <lastmod>2021-06-09T09:52:49-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bofa-napa-biopharma-conference</loc>
  <lastmod>2021-06-09T14:00:25-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/jmp-securities-life-sciences-conference</loc>
  <lastmod>2021-06-14T09:31:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/hc-wainwright-23rd-annual-global-investment-conference</loc>
  <lastmod>2021-08-18T10:44:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bridgebio-pharma-inc-rd-day-0</loc>
  <lastmod>2021-10-12T14:47:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/chardan-5th-annual-genetic-medicines-conference</loc>
  <lastmod>2021-08-25T15:41:51-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/jefferies-fireside-chat-bridgebio-discuss-acoramidis-program</loc>
  <lastmod>2021-10-15T09:17:57-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/h-c-wainwright-2nd-annual-precision-oncology-conference</loc>
  <lastmod>2021-10-15T12:42:15-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/jefferies-london-healthcare-conference</loc>
  <lastmod>2021-11-11T12:28:48-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/jp-morgan-40th-annual-healthcare-conference</loc>
  <lastmod>2021-12-17T14:39:34-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bridgebio-pharma-discuss-topline-results-phase-3-attribute-cm-study</loc>
  <lastmod>2021-12-27T07:07:18-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/svb-leerink-11th-annual-global-healthcare-conference</loc>
  <lastmod>2022-01-24T09:41:39-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/citi-attr-cm-co-panel-day</loc>
  <lastmod>2022-04-21T14:09:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bank-america-2022-healthcare-conference</loc>
  <lastmod>2022-05-10T14:02:04-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/h-c-wainwright-global-investment-conference</loc>
  <lastmod>2022-05-18T08:51:53-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/jefferies-healthcare-conference</loc>
  <lastmod>2022-06-08T16:24:15-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/ubs-global-healthcare-conference</loc>
  <lastmod>2022-05-23T18:34:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bridgebio-pharma-discuss-phase-2-data-bbp-418-limb-girdle-muscular-dystrophy</loc>
  <lastmod>2022-05-16T16:04:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/goldman-sachs-global-healthcare-conference</loc>
  <lastmod>2022-06-14T09:48:56-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bridgebio-pharma-discuss-phase-2b-data-and-phase-3-trial-design-encaleret-adh1</loc>
  <lastmod>2022-06-13T16:26:54-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/citis-17th-annual-biopharma-conference</loc>
  <lastmod>2022-09-06T07:30:49-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/morgan-stanley-global-healthcare-conference</loc>
  <lastmod>2022-09-06T07:30:52-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/hc-wainwright-24th-annual-global-investment-conference</loc>
  <lastmod>2022-09-06T07:30:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/baird-global-healthcare-conference</loc>
  <lastmod>2022-09-08T13:32:50-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/jefferies-genetic-cell-and-medicine-summit</loc>
  <lastmod>2022-09-21T11:10:06-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bridgebio-pharma-discuss-new-data-its-novel-approaches-ras-driven-cancers</loc>
  <lastmod>2022-10-17T16:23:16-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/jefferies-health-care-conference</loc>
  <lastmod>2022-11-07T09:12:56-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/evercore-isi-healthconx-conference</loc>
  <lastmod>2022-11-04T13:30:50-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/jp-morgan-healthcare-conference</loc>
  <lastmod>2023-01-08T21:55:20-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/cowen-43rd-annual-healthcare-conference</loc>
  <lastmod>2023-01-30T12:23:16-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/svb-securities-global-biopharma-conference</loc>
  <lastmod>2023-01-30T14:35:10-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bridgebio-achondroplasia-roundtable-event</loc>
  <lastmod>2023-02-16T15:00:25-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bridgebio-shares-phase-2-data-infigratinib-achondroplasia</loc>
  <lastmod>2023-03-05T21:07:47-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bridgebio-pharma-discuss-novel-bioassay-phase-2-data-and-preliminary-phase-3</loc>
  <lastmod>2023-03-21T09:14:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bank-america-merrill-lynch-global-healthcare-conference-2023</loc>
  <lastmod>2023-04-27T07:30:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bridgebio-pharma-shares-topline-30-month-results-phase-3-attribute-cm-study</loc>
  <lastmod>2023-07-17T07:02:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bridgebio-pharma-discuss-attribute-cm-phase-3-results-presented-esc</loc>
  <lastmod>2023-08-28T07:08:56-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/morgan-stanley-21st-annual-global-healthcare-conference-2023</loc>
  <lastmod>2023-11-09T07:57:31-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bridgebio-pharma-discuss-attribute-cm-phase-3-results-presented-aha</loc>
  <lastmod>2023-11-11T19:21:48-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/evercore-isi-healthconx-conference-0</loc>
  <lastmod>2023-11-20T16:20:51-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/jp-morgan-healthcare-conference-0</loc>
  <lastmod>2024-01-07T22:37:18-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/td-cowen-44th-annual-healthcare-conference</loc>
  <lastmod>2024-03-04T11:48:56-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/cantors-virtual-muscular-dystrophy-symposium</loc>
  <lastmod>2024-04-01T15:28:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bank-america-merrill-lynch-healthcare-conference-2024</loc>
  <lastmod>2024-05-15T12:03:28-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bridgebio-pharma-discuss-additional-data-attribute-cm-presented-isa-2024</loc>
  <lastmod>2024-05-30T20:17:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bridgebio-pharma-discuss-month-12-and-18-phase-2-cohort-5-results-infigratinib</loc>
  <lastmod>2024-06-03T19:57:27-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/goldman-sachs-45th-annual-global-healthcare-conference</loc>
  <lastmod>2024-06-06T07:30:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/morgan-stanley-22nd-annual-global-health-care-conference</loc>
  <lastmod>2024-08-28T07:30:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/cantor-global-healthcare-conference</loc>
  <lastmod>2024-08-28T07:30:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/bridgebio-management-remarks-attrubytm-acoramidis</loc>
  <lastmod>2024-11-22T19:38:02-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/jp-morgan-healthcare-conference-1</loc>
  <lastmod>2025-01-13T11:06:07-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/td-cowen-45th-annual-healthcare-conference</loc>
  <lastmod>2025-01-31T16:30:07-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/leerink-partners-global-healthcare-conference</loc>
  <lastmod>2025-01-31T14:49:03-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/events/event-details/raymond-james-46th-annual-institutional-investors-conference</loc>
  <lastmod>2025-02-03T12:53:24-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/investor-relations</loc>
  <lastmod>2025-01-31T16:34:49-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/press-releases</loc>
  <lastmod>2022-07-12T03:51:16-04:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-and-events/event-calendar</loc>
  <lastmod>2024-06-03T16:26:56-04:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/presentations</loc>
  <lastmod>2025-02-20T07:31:58-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/corporate-governance</loc>
  <lastmod>2024-11-25T18:53:50-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/corporate-governance/board-of-directors</loc>
  <lastmod>2023-05-15T12:07:44-04:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/stock-information/analyst-coverage</loc>
  <lastmod>2022-07-12T03:52:36-04:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/stock-information/stock-quote-chart</loc>
  <lastmod>2019-06-25T14:02:33-04:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/investor-resources/email-alerts</loc>
  <lastmod>2025-01-14T08:44:01-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/shareholder-services/rss-feeds</loc>
  <lastmod>2017-12-29T16:26:13-05:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/investor-resources/investor-contact</loc>
  <lastmod>2022-03-23T19:03:49-04:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/financials-and-filings/sec-filings</loc>
  <lastmod>2022-03-21T00:42:30-04:00</lastmod>
  <priority>0.8</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-initiates-attribute-cm-phase-3-study-ag10</loc>
  <lastmod>2019-04-22T13:42:03-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/phoenix-tissue-repair-doses-first-patient-phase-12-clinical</loc>
  <lastmod>2019-04-22T13:42:37-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-closes-2992-million-financing-round-support-its</loc>
  <lastmod>2019-04-22T13:43:24-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-present-37th-annual-jp-morgan-healthcare</loc>
  <lastmod>2019-04-22T13:46:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/qed-therapeutics-announces-collaboration-foundation-medicine</loc>
  <lastmod>2019-04-22T13:46:45-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-appoints-william-lis-board-directors</loc>
  <lastmod>2019-04-22T13:47:24-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/pellepharm-present-piper-jaffray-healthcare-conference</loc>
  <lastmod>2019-04-22T13:48:08-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/leo-pharma-and-pellepharm-announce-760-million-collaboration</loc>
  <lastmod>2019-04-22T13:48:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-present-two-upcoming-investor-conferences</loc>
  <lastmod>2019-04-22T13:52:41-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-llc-signs-joint-collaboration-agreement</loc>
  <lastmod>2019-04-22T13:53:30-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-announces-positive-phase-2-data-ag10</loc>
  <lastmod>2019-04-22T13:54:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-reports-third-quarter-2018-financial-results</loc>
  <lastmod>2019-04-22T13:55:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-host-conference-call-and-webcast-discuss</loc>
  <lastmod>2019-04-22T13:55:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-receives-positive-opinion-orphan-designation</loc>
  <lastmod>2019-04-22T13:56:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/data-published-nature-communications-demonstrates-coa</loc>
  <lastmod>2019-04-22T13:57:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/qed-therapeutics-presents-data-infigratinib-cholangiocarcinoma</loc>
  <lastmod>2019-04-22T13:58:17-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/pellepharm-presents-updated-data-two-phase-2-studies</loc>
  <lastmod>2019-04-22T13:59:06-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-present-phase-2-data-ag10-ttr-amyloidosis</loc>
  <lastmod>2019-04-22T14:00:45-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/fda-grants-orphan-drug-designation-eidos-therapeutics-product</loc>
  <lastmod>2019-04-22T14:01:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-present-leerink-partners-roundtable-series</loc>
  <lastmod>2019-04-22T14:02:07-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/pellepharm-present-cantor-fitzgerald-global-healthcare</loc>
  <lastmod>2019-04-22T14:03:09-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-presents-data-its-phase-1-clinical-trial-ag10</loc>
  <lastmod>2019-04-22T14:03:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-announces-publication-ag10-molecular-design</loc>
  <lastmod>2019-04-22T14:04:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/qed-tx-new-company-working-treatment-achondroplasia</loc>
  <lastmod>2019-04-22T14:06:43-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-reports-second-quarter-2018-financial-results</loc>
  <lastmod>2019-04-22T14:07:30-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-announces-closing-initial-public-offering-and</loc>
  <lastmod>2019-04-22T14:08:04-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-announces-pricing-initial-public-offering</loc>
  <lastmod>2019-04-22T14:09:49-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/neurovive-out-licenses-targeted-lhon-therapy-bridgebio-pharmas</loc>
  <lastmod>2019-04-22T14:09:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-launches-coa-therapeutics-target-coenzyme-rare</loc>
  <lastmod>2019-04-22T14:10:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/pellepharm-participate-cantor-fitzgerald-dermatology-and</loc>
  <lastmod>2019-04-22T14:11:32-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-enters-agreement-acquire-late-stage-therapy</loc>
  <lastmod>2019-04-22T14:12:06-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/pellepharm-present-2018-ubs-global-healthcare-conference</loc>
  <lastmod>2019-04-22T14:12:59-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/pellepharm-present-topical-patidegib-and-skin-cancer</loc>
  <lastmod>2019-04-22T14:13:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-initiates-phase-2-clinical-trial-ag10</loc>
  <lastmod>2019-04-22T14:14:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-completes-64m-series-b-financing</loc>
  <lastmod>2019-04-22T14:14:54-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-host-symposium-ttr-stabilization-16th</loc>
  <lastmod>2019-04-22T14:15:32-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-licenses-late-stage-oncology-drug-infigratinib</loc>
  <lastmod>2019-04-22T14:16:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-present-36th-annual-jp-morgan-healthcare</loc>
  <lastmod>2019-04-22T14:17:21-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-appoints-sanuj-ravindran-md-and-eric-michael</loc>
  <lastmod>2019-04-22T14:17:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/pellepharm-appoints-sanuj-k-ravindran-md-president-and-chief</loc>
  <lastmod>2019-04-22T14:18:37-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/fda-grants-breakthrough-therapy-designation-and-orphan-drug</loc>
  <lastmod>2019-04-22T14:19:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/preclinical-data-demonstrates-potential-eidos-therapeutics-lead</loc>
  <lastmod>2019-04-22T14:19:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-present-data-its-potential-treatment</loc>
  <lastmod>2019-04-22T14:20:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/md-anderson-and-bridgebio-pharma-launch-navire-pharma-develop</loc>
  <lastmod>2019-04-22T14:20:58-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/eidos-therapeutics-initiates-first-clinical-study-ag10-targeting</loc>
  <lastmod>2019-04-22T14:22:06-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-expands-investor-base-raising-additional-135</loc>
  <lastmod>2019-04-22T14:23:29-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/pellepharm-announces-topline-results-phase-2-study-topical</loc>
  <lastmod>2019-04-22T14:24:32-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-launches-eidos-therapeutics-develop-targeted</loc>
  <lastmod>2019-04-22T14:25:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/redirecting-n-acetylaspartate-metabolism-central-nervous-system</loc>
  <lastmod>2019-04-22T14:26:21-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-launches-focus-precision-medicines-genetic</loc>
  <lastmod>2019-04-22T14:26:50-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/pellepharm-launches-financing-bridgebio-pharma-develop-topical</loc>
  <lastmod>2019-04-22T14:27:22-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-filing-registration-statement</loc>
  <lastmod>2019-06-25T13:15:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-pricing-its-initial-public-offering</loc>
  <lastmod>2019-06-26T23:25:06-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-expands-its-research-neuromuscular-disease</loc>
  <lastmod>2019-09-05T09:13:16-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharmas-origin-biosciences-presents-new-data-natural</loc>
  <lastmod>2019-09-06T20:05:52-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/alexion-and-bridgebio-announce-japanese-license-agreement-eidos</loc>
  <lastmod>2019-09-09T11:20:27-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/ivy-brain-tumor-center-and-bridgebio-subsidiary-qed-therapeutics</loc>
  <lastmod>2019-09-24T07:00:34-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-terminates-merger-process-its-subsidiary-eidos</loc>
  <lastmod>2019-10-14T07:37:21-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/qed-and-parent-company-bridgebio-announce-preclinical-data</loc>
  <lastmod>2019-10-17T07:04:46-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-gene-therapy-subsidiaries-present-data</loc>
  <lastmod>2019-10-22T07:31:05-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-third-quarter-2019-financial-results</loc>
  <lastmod>2019-11-07T16:13:31-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/correction-bridgebio-and-eidos-present-data-phase-2-open-label</loc>
  <lastmod>2019-11-16T22:24:12-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing</loc>
  <lastmod>2019-11-27T16:30:13-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/pellepharm-completes-enrollment-pivotal-phase-3-clinical-trial</loc>
  <lastmod>2019-12-02T08:00:45-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharmas-origin-biosciences-initiates-rolling</loc>
  <lastmod>2019-12-03T07:30:18-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-0</loc>
  <lastmod>2019-12-05T19:34:46-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-appoints-eli-wallace-chief-scientific</loc>
  <lastmod>2019-12-09T07:30:16-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-appoints-industry-leader-jennifer-cook-new</loc>
  <lastmod>2019-12-16T07:30:24-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharmas-origin-biosciences-enters-partnership-medison</loc>
  <lastmod>2019-12-18T07:30:21-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-present-upcoming-investor-conference</loc>
  <lastmod>2019-12-19T16:30:36-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharmas-qed-therapeutics-receives-fast-track</loc>
  <lastmod>2020-01-06T07:30:22-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/pellepharm-initiates-phase-2-clinical-trial-patidegib-topical</loc>
  <lastmod>2020-01-08T08:01:29-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharmas-gene-therapy-subsidiaries-enter-strategic</loc>
  <lastmod>2020-01-10T07:30:18-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-grows-pipeline-20-genetic-medicines-four-assets</loc>
  <lastmod>2020-01-13T07:30:24-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-1</loc>
  <lastmod>2020-02-05T18:31:02-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-eidos-therapeutics-present-upcoming</loc>
  <lastmod>2020-02-21T19:25:21-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-appoints-ronald-j-daniels-its-board</loc>
  <lastmod>2020-02-24T07:30:20-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-fourth-quarter-and-full-year-2019</loc>
  <lastmod>2020-03-02T08:29:07-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-2</loc>
  <lastmod>2020-03-03T16:30:18-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-announces-proposed-offering-350-million</loc>
  <lastmod>2020-03-04T07:00:38-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-prices-upsized-offering-475-million</loc>
  <lastmod>2020-03-04T23:31:33-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharmas-qed-therapeutics-announces-dosing-first</loc>
  <lastmod>2020-03-12T07:30:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-3</loc>
  <lastmod>2020-04-03T16:30:17-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-4</loc>
  <lastmod>2020-05-05T16:30:56-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-present-upcoming-investor-conference-0</loc>
  <lastmod>2020-05-06T16:47:47-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharmas-qed-therapeutics-announces-preclinical-data</loc>
  <lastmod>2020-05-11T07:30:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-reports-first-quarter-2020-financial</loc>
  <lastmod>2020-05-14T11:01:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharmas-phoenix-tissue-repair-provides-updates-its</loc>
  <lastmod>2020-05-13T16:10:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharmas-qed-therapeutics-presents-data-infigratinib</loc>
  <lastmod>2020-05-29T07:30:15-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-5</loc>
  <lastmod>2020-06-05T16:30:17-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharmas-ml-bio-solutions-announces-dosing-first</loc>
  <lastmod>2020-06-11T10:16:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-enters-collaboration-agreement-johns</loc>
  <lastmod>2020-06-18T07:30:22-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-university-florida-establish-collaboration</loc>
  <lastmod>2020-06-18T07:35:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-appoints-biotech-trailblazers-brent</loc>
  <lastmod>2020-06-24T07:30:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-6</loc>
  <lastmod>2020-07-06T16:30:17-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharmas-phoenix-tissue-repair-highlight-interim-phase</loc>
  <lastmod>2020-07-10T07:30:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharmas-qed-therapeutics-doses-first-child-phase-2</loc>
  <lastmod>2020-07-15T08:07:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/ivy-brain-tumor-center-and-bridgebio-pharmas-qed-therapeutics</loc>
  <lastmod>2020-07-28T07:30:15-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-expands-reach-china-and-other-major-asian</loc>
  <lastmod>2020-08-11T07:35:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-reports-second-quarter-2020-financial</loc>
  <lastmod>2020-08-11T07:40:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-7</loc>
  <lastmod>2020-08-12T16:30:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-8</loc>
  <lastmod>2020-09-03T17:30:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharmas-calcilytix-therapeutics-initiates-phase-2</loc>
  <lastmod>2020-09-21T07:30:24-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-host-virtual-rd-day-september-29-2020</loc>
  <lastmod>2020-09-22T07:30:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-affiliate-origin-biosciences-announces-fda</loc>
  <lastmod>2020-09-29T07:30:20-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-eidos-therapeutics-announce-merger</loc>
  <lastmod>2020-10-05T07:04:34-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/salk-institute-and-bridgebio-pharma-collaborate-advance</loc>
  <lastmod>2020-10-21T11:18:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-and-university-colorado-anschutz-medical</loc>
  <lastmod>2020-10-21T07:30:26-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-affiliate-phoenix-tissue-repair-announce</loc>
  <lastmod>2020-10-27T07:30:17-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-9</loc>
  <lastmod>2020-11-04T16:30:40-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-reports-third-quarter-2020-financial</loc>
  <lastmod>2020-11-05T07:30:29-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-affiliate-navire-pharma-announce-dosing</loc>
  <lastmod>2020-11-13T07:30:14-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-affiliate-qed-therapeutics-announce-fda</loc>
  <lastmod>2020-12-01T07:30:20-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-10</loc>
  <lastmod>2020-12-04T16:30:19-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-maze-therapeutics-establish-joint-venture</loc>
  <lastmod>2020-12-07T08:30:23-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/ucsf-and-bridgebio-pharma-collaborate-accelerate-development</loc>
  <lastmod>2020-12-23T07:30:32-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/leading-independent-proxy-advisory-firm-iss-recommends-bridgebio</loc>
  <lastmod>2021-01-04T07:30:36-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-11</loc>
  <lastmod>2021-01-06T16:30:48-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-and-eidos-therapeutics-inc-announce-january</loc>
  <lastmod>2021-01-13T16:30:35-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/stockholders-bridgebio-pharma-inc-and-eidos-therapeutics-inc</loc>
  <lastmod>2021-01-19T16:01:33-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-announces-proposed-offering-400-million</loc>
  <lastmod>2021-01-25T07:00:54-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-prices-upsized-offering-650-million</loc>
  <lastmod>2021-01-25T23:04:35-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-announces-completion-merger-eidos</loc>
  <lastmod>2021-01-26T08:30:52-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-affiliate-venthera-announce-dosing-first</loc>
  <lastmod>2021-02-02T07:30:45-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-12</loc>
  <lastmod>2021-02-05T16:30:53-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-announces-launch-secondary-offering-common</loc>
  <lastmod>2021-02-11T16:10:37-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-announces-pricing-secondary-offering-common</loc>
  <lastmod>2021-02-12T08:00:44-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-affiliate-ml-bio-solutions-announce-dosing</loc>
  <lastmod>2021-02-19T07:30:38-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announce-proof-concept-data-adh1-endocrine</loc>
  <lastmod>2021-02-24T16:01:36-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-reports-fourth-quarter-and-full-year-2020</loc>
  <lastmod>2021-02-25T07:30:51-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-affiliate-origin-biosciences-announce-fda</loc>
  <lastmod>2021-06-07T16:53:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-13</loc>
  <lastmod>2021-03-02T16:30:35-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-proof-concept-data-encaleret-adh1</loc>
  <lastmod>2021-03-20T11:00:46-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharmas-affiliate-qed-therapeutics-and-helsinn-group</loc>
  <lastmod>2021-03-31T07:30:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-14</loc>
  <lastmod>2021-04-06T16:30:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-brown-university-announce-partnership-drive</loc>
  <lastmod>2021-04-13T07:30:43-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-and-glyconet-initiate-collaboration</loc>
  <lastmod>2021-04-13T07:32:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-and-lundquist-institute-collaborate-advance</loc>
  <lastmod>2021-04-13T07:35:53-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-and-oregon-health-science-university</loc>
  <lastmod>2021-04-13T07:37:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-and-roswell-park-establish-collaboration</loc>
  <lastmod>2021-04-13T07:40:53-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-and-uc-davis-establish-collaboration</loc>
  <lastmod>2021-04-13T07:42:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-university-california-san-diego-announce</loc>
  <lastmod>2021-04-13T07:45:43-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-reports-first-quarter-2021-financial</loc>
  <lastmod>2021-05-06T07:31:00-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-receives-fda-fast-track-designation</loc>
  <lastmod>2021-05-14T07:30:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-15</loc>
  <lastmod>2021-05-14T16:30:15-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharmas-affiliate-qed-therapeutics-and-partner-helsinn</loc>
  <lastmod>2021-05-28T14:30:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-receives-fda-fast-track-designation-encaleret</loc>
  <lastmod>2021-06-01T07:30:24-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-16</loc>
  <lastmod>2021-06-14T16:35:25-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-collaborations-three-academic</loc>
  <lastmod>2021-07-08T07:31:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-17</loc>
  <lastmod>2021-07-12T16:31:51-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-announces-clinical-collaboration-bristol-myers-squibb</loc>
  <lastmod>2021-07-27T07:32:28-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-18</loc>
  <lastmod>2021-08-04T19:03:51-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-reports-second-quarter-2021-financial</loc>
  <lastmod>2021-08-05T07:33:24-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-appoints-finance-and-pharmaceutical-leaders</loc>
  <lastmod>2021-08-18T07:31:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-lianbio-announce-first-patient-treated</loc>
  <lastmod>2021-08-25T08:11:28-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-19</loc>
  <lastmod>2021-09-08T17:00:48-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-receives-fda-fast-track-designation-0</loc>
  <lastmod>2021-09-15T07:32:25-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/helsinn-group-bridgebio-pharma</loc>
  <lastmod>2021-09-29T08:52:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-updated-phase-2b-data-encaleret</loc>
  <lastmod>2021-10-01T17:01:04-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-host-virtual-rd-day-october-12-2021</loc>
  <lastmod>2021-10-06T07:32:15-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-first-publication-preclinical-data</loc>
  <lastmod>2021-10-07T09:03:54-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-progress-its-kras-portfolio-new-gene</loc>
  <lastmod>2021-10-12T07:32:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-appoints-pioneering-national-leader</loc>
  <lastmod>2021-10-25T07:32:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-collaborations-columbia-university</loc>
  <lastmod>2021-10-29T07:31:53-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-dosing-first-patient-phase-12-trial</loc>
  <lastmod>2021-11-03T08:28:30-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-third-quarter-2021-financial-results</loc>
  <lastmod>2021-11-04T07:34:07-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-secures-750-million-non-dilutive-debt</loc>
  <lastmod>2021-11-18T07:31:02-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-helsinn-group-announce-strategic</loc>
  <lastmod>2021-11-19T07:30:36-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-20</loc>
  <lastmod>2021-12-10T07:30:39-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-month-12-topline-results-phase-3</loc>
  <lastmod>2021-12-27T07:01:01-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-announces-clinical-collaboration-amgen-study-bbp-398</loc>
  <lastmod>2022-01-13T07:31:25-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-dosing-first-patient-phase-12-trial-0</loc>
  <lastmod>2022-01-27T07:31:55-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-fourth-quarter-and-full-year-2021</loc>
  <lastmod>2022-02-24T07:32:23-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-sentynl-therapeutics-announce-asset</loc>
  <lastmod>2022-03-08T07:30:27-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-host-investor-call-discuss-phase-2-data</loc>
  <lastmod>2022-03-11T07:32:10-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-positive-phase-2-data-limb-girdle</loc>
  <lastmod>2022-03-14T07:31:53-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-present-updated-results-phase-2-open-label</loc>
  <lastmod>2022-03-28T07:31:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-presents-updated-results-phase-2-open-label</loc>
  <lastmod>2022-04-03T08:38:05-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-first-quarter-2022-financial-results</loc>
  <lastmod>2022-05-05T11:22:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-participate-bank-america-securities-healthcare</loc>
  <lastmod>2022-05-11T09:18:16-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-announces-exclusive-license-agreement-bristol-myers</loc>
  <lastmod>2022-05-12T07:30:29-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-sells-rare-pediatric-disease-priority-review</loc>
  <lastmod>2022-05-13T07:30:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-participate-may-investor-events</loc>
  <lastmod>2022-05-17T07:30:53-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-affiliate-phoenix-tissue-repair-announces</loc>
  <lastmod>2022-05-20T07:30:36-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-presents-positive-phase-1-data-healthy</loc>
  <lastmod>2022-05-26T13:00:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-participate-june-investor-events</loc>
  <lastmod>2022-06-06T07:30:15-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-present-phase-2b-data-and-pivotal-phase-3-study</loc>
  <lastmod>2022-06-09T07:30:52-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-affiliate-venthera-presents-preliminary-results</loc>
  <lastmod>2022-06-10T07:30:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-shares-positive-phase-2b-data-and-announces</loc>
  <lastmod>2022-06-13T08:00:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-early-positive-data-bbp-812-its</loc>
  <lastmod>2022-06-22T07:30:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-positive-phase-1-data-and-phase-23</loc>
  <lastmod>2022-06-27T07:30:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-academic-collaboration-baylor-college</loc>
  <lastmod>2022-07-21T07:30:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-founding-affiliation-bakar-labs</loc>
  <lastmod>2022-07-21T07:30:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-sentynl-therapeutics-receive-positive-chmp</loc>
  <lastmod>2022-07-25T07:30:42-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-positive-interim-results-phase-2</loc>
  <lastmod>2022-07-26T07:30:43-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-reports-second-quarter-2022-financial</loc>
  <lastmod>2022-08-04T07:56:43-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-sentynl-therapeutics-and-medison-pharma</loc>
  <lastmod>2022-08-10T07:30:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-dosing-first-patient-phase-1-trial</loc>
  <lastmod>2022-08-18T07:30:37-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-participate-september-investor-events</loc>
  <lastmod>2022-09-06T07:30:59-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-sentynl-therapeutics-receive-marketing</loc>
  <lastmod>2022-09-20T07:30:41-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-present-new-data-its-novel-approaches-ras</loc>
  <lastmod>2022-10-07T07:30:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-first-lung-cancer-patient-dosed-phase</loc>
  <lastmod>2022-10-11T07:30:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-presents-updated-positive-data-its-bbp-812</loc>
  <lastmod>2022-10-13T16:00:31-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-presents-12-month-results-phase-2-study-bbp-418</loc>
  <lastmod>2022-10-14T07:30:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-highlights-its-ras-precision-oncology-portfolio</loc>
  <lastmod>2022-10-17T12:30:57-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-inc-reports-third-quarter-2022-financial</loc>
  <lastmod>2022-11-03T07:46:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-participate-november-investor-events</loc>
  <lastmod>2022-11-09T07:30:20-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-initiates-calibrate-pivotal-phase-3-study</loc>
  <lastmod>2022-12-22T07:30:33-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-present-jp-morgan-healthcare-conference</loc>
  <lastmod>2023-01-08T21:56:57-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-participate-february-and-march-investor-events</loc>
  <lastmod>2023-02-27T12:45:31-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-host-educational-roundtable-esteemed</loc>
  <lastmod>2023-02-13T07:30:16-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-21</loc>
  <lastmod>2023-02-17T07:30:15-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-fourth-quarter-and-full-year-2022</loc>
  <lastmod>2023-02-23T07:30:44-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-host-investor-call-discuss-phase-2-cohort-5-data</loc>
  <lastmod>2023-03-03T07:30:31-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-announces-positive-phase-2-cohort-5-results</loc>
  <lastmod>2023-03-06T07:01:18-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-proposed-public-offering-common-stock</loc>
  <lastmod>2023-03-06T16:07:14-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-pricing-public-offering-common-stock</loc>
  <lastmod>2023-03-08T07:00:50-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-present-preliminary-findings-its-novel-bioassay</loc>
  <lastmod>2023-03-17T07:30:34-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-shares-preliminary-findings-novel-bioassay</loc>
  <lastmod>2023-03-21T07:30:43-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-first-lung-cancer-patient-dosed-0</loc>
  <lastmod>2023-03-23T07:30:31-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-22</loc>
  <lastmod>2023-04-07T07:30:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-23</loc>
  <lastmod>2023-04-11T07:30:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-participate-bank-america-merrill-lynch-global</loc>
  <lastmod>2023-04-27T07:30:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-first-quarter-2023-financial-results</loc>
  <lastmod>2023-05-04T07:30:25-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-24</loc>
  <lastmod>2023-05-11T07:30:37-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-present-updated-data-its-bbp-812-canavan</loc>
  <lastmod>2023-05-15T07:30:51-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-presents-updated-encouraging-clinical-and</loc>
  <lastmod>2023-05-22T07:30:34-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-present-updated-six-month-results-its-phase-2</loc>
  <lastmod>2023-06-08T07:30:30-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-25</loc>
  <lastmod>2023-06-13T07:30:37-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-presents-updated-six-month-results-its-phase-2</loc>
  <lastmod>2023-06-20T07:31:03-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/burjeel-holdings-launch-rare-disease-research-development</loc>
  <lastmod>2023-07-12T16:31:16-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-host-investor-call-share-topline-30-month-results</loc>
  <lastmod>2023-07-14T16:01:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-announces-consistently-positive-results-phase-3</loc>
  <lastmod>2023-07-17T07:00:48-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-26</loc>
  <lastmod>2023-07-18T07:30:17-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-opportunity-accelerated-approval</loc>
  <lastmod>2023-07-31T07:30:36-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-second-quarter-2023-financial-results</loc>
  <lastmod>2023-08-03T07:30:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-27</loc>
  <lastmod>2023-08-04T07:30:32-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-present-detailed-results-phase-3-attribute</loc>
  <lastmod>2023-08-24T16:01:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-presents-detailed-positive-results-phase-3-attribute</loc>
  <lastmod>2023-08-27T06:15:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-positive-feedback-us-fda-and-eu-ema</loc>
  <lastmod>2023-09-06T07:30:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-participate-morgan-stanley-21st-annual-global</loc>
  <lastmod>2023-09-07T07:30:23-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-28</loc>
  <lastmod>2023-09-08T07:30:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-250-million-private-placement-equity</loc>
  <lastmod>2023-09-25T07:30:39-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-and-resilience-announce-strategic-multi-year</loc>
  <lastmod>2023-10-03T07:30:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-shares-positive-long-term-data-ongoing-phase-2</loc>
  <lastmod>2023-10-09T07:30:30-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-new-england-journal-medicine</loc>
  <lastmod>2023-10-10T07:30:10-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-29</loc>
  <lastmod>2023-10-11T07:30:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-third-quarter-2023-financial-results</loc>
  <lastmod>2023-11-02T07:30:27-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-30</loc>
  <lastmod>2023-11-08T07:31:02-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-present-additional-data-phase-3-attribute-cm</loc>
  <lastmod>2023-11-09T07:30:39-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-presents-additional-clinical-outcomes-data</loc>
  <lastmod>2023-11-12T10:30:22-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-submission-new-drug-application-nda</loc>
  <lastmod>2023-12-05T07:45:41-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-31</loc>
  <lastmod>2023-12-08T07:30:31-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-announces-first-child-dosed-propel-3-its-phase-3</loc>
  <lastmod>2023-12-13T07:30:36-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-announces-fda-clearance-ind-application-bbo-8520-first</loc>
  <lastmod>2024-01-03T07:30:38-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-participate-jp-morgan-healthcare-conference</loc>
  <lastmod>2024-01-03T16:30:34-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-32</loc>
  <lastmod>2024-01-10T07:30:54-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-publication-positive-results-phase-3</loc>
  <lastmod>2024-01-10T17:16:30-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-secures-125-billion-capital-blue-owl-and-cpp</loc>
  <lastmod>2024-01-18T07:00:43-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-shares-positive-results-single-arm-phase-3</loc>
  <lastmod>2024-02-02T07:01:04-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-us-food-and-drug-administration-fda</loc>
  <lastmod>2024-02-05T07:30:43-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-33</loc>
  <lastmod>2024-02-06T07:30:55-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-kyowa-kirin-announce-partnership-upfront</loc>
  <lastmod>2024-02-07T07:35:04-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-fourth-quarter-and-full-year-2023</loc>
  <lastmod>2024-02-22T07:30:46-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-and-bayer-announce-european-licensing-agreement</loc>
  <lastmod>2024-03-04T02:30:14-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-proposed-public-offering-common-0</loc>
  <lastmod>2024-03-04T16:18:08-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-pricing-public-offering-common-0</loc>
  <lastmod>2024-03-05T23:54:16-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-34</loc>
  <lastmod>2024-03-20T07:30:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-presents-cardiac-magnetic-resonance-cmr-imaging</loc>
  <lastmod>2024-04-16T06:47:02-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-35</loc>
  <lastmod>2024-04-10T07:30:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-launches-bridgebio-oncology-therapeutics-bbot-200m</loc>
  <lastmod>2024-05-02T19:36:56-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-first-quarter-2024-financial-results</loc>
  <lastmod>2024-05-02T07:30:29-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-presents-additional-data-and-analyses-its-phase</loc>
  <lastmod>2024-05-13T07:30:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-participate-bank-america-merrill-lynch-global-0</loc>
  <lastmod>2024-05-14T07:30:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-36</loc>
  <lastmod>2024-05-15T07:30:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-present-additional-analyses-phase-3-attribute</loc>
  <lastmod>2024-05-24T07:30:36-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/additional-data-showing-acoramidis-increases-serum-transthyretin</loc>
  <lastmod>2024-05-29T16:01:45-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-host-call-month-12-and-18-phase-2-cohort-5-results</loc>
  <lastmod>2024-06-03T16:01:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-announces-durable-month-12-and-18-phase-2-cohort-5</loc>
  <lastmod>2024-06-04T07:30:32-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-participate-45th-annual-goldman-sachs-global</loc>
  <lastmod>2024-06-06T07:30:18-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-37</loc>
  <lastmod>2024-06-10T07:30:51-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-surpasses-interim-analysis-enrollment-target</loc>
  <lastmod>2024-06-18T07:30:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-38</loc>
  <lastmod>2024-07-05T16:31:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-announces-appointment-thomas-trimarchi-phd-president</loc>
  <lastmod>2024-07-23T07:30:19-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-second-quarter-2024-financial-results</loc>
  <lastmod>2024-08-01T07:30:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-39</loc>
  <lastmod>2024-08-08T07:30:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-launches-myachonjourney-new-resource-families</loc>
  <lastmod>2024-08-19T09:08:56-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-partners-leading-cardiovascular-data-science-lab-cards</loc>
  <lastmod>2024-08-26T07:30:38-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-participate-september-investor-events-0</loc>
  <lastmod>2024-08-28T07:30:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-present-additional-analyses-phase-3-attribute-cm-trial</loc>
  <lastmod>2024-08-29T07:30:13-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-shares-data-serum-ttr-increase-when-switching</loc>
  <lastmod>2024-08-30T10:50:11-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-inducement-grants-under-nasdaq-40</loc>
  <lastmod>2024-09-06T07:30:35-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-receives-fdas-regenerative-medicine-advanced-therapy</loc>
  <lastmod>2024-09-10T16:45:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-topline-results-phase-12-trial</loc>
  <lastmod>2024-09-10T16:45:14-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-announces-infigratinib-first-ever-investigational</loc>
  <lastmod>2024-09-17T07:30:32-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-shares-recurrent-event-analysis-attribute-cm</loc>
  <lastmod>2024-09-27T18:00:33-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-completes-enrollment-fortify-phase-3-registrational</loc>
  <lastmod>2024-09-30T07:30:08-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-present-outcomes-data-through-42-months-open-label</loc>
  <lastmod>2024-10-03T07:30:39-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-shares-positive-data-high-dose-cohort-phase-12</loc>
  <lastmod>2024-10-24T07:30:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-announces-publication-case-study-exploring-portfolio</loc>
  <lastmod>2024-11-05T07:30:36-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-third-quarter-2024-financial-results</loc>
  <lastmod>2024-11-12T07:31:02-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-announces-publication-new-england-journal</loc>
  <lastmod>2024-11-18T05:30:21-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/open-label-extension-data-confirms-sustained-benefit-acoramidis</loc>
  <lastmod>2024-11-18T13:54:57-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/attrubytm-acoramidis-near-complete-ttr-stabilizer-90-approved</loc>
  <lastmod>2024-11-22T19:12:36-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/acoramidis-receives-positive-chmp-opinion-treatment</loc>
  <lastmod>2024-12-13T07:18:45-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-participate-jp-morgan-healthcare-conference-0</loc>
  <lastmod>2025-01-08T07:30:55-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-announces-commercial-progress-program-updates-and-2025</loc>
  <lastmod>2025-01-13T12:22:13-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/beyonttratm-acoramidis-first-near-complete-ttr-stabilizer-90</loc>
  <lastmod>2025-02-11T10:01:07-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-report-fourth-quarter-and-full-year-2024</loc>
  <lastmod>2025-02-13T16:14:18-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-pharma-reports-fourth-quarter-and-full-year-2024</loc>
  <lastmod>2025-02-20T07:30:45-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-initiates-long-term-debt-management-strategy-and</loc>
  <lastmod>2025-02-24T16:10:43-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/news-releases/news-release-details/bridgebio-prices-offering-500-million-convertible-senior-notes</loc>
  <lastmod>2025-02-26T02:50:01-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-18-017265</loc>
  <lastmod>2018-06-19T21:34:23-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-18-018143</loc>
  <lastmod>2018-06-26T16:36:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13d/0001193125-18-233959</loc>
  <lastmod>2018-08-01T08:06:39-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-18-030324</loc>
  <lastmod>2018-12-06T20:52:46-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13da/0001193125-18-344046</loc>
  <lastmod>2018-12-07T06:06:41-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-18-030596</loc>
  <lastmod>2018-12-10T19:29:50-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13da/0001193125-18-346386</loc>
  <lastmod>2018-12-11T06:14:07-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-18-030738</loc>
  <lastmod>2018-12-12T17:47:54-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13da/0001193125-18-347912</loc>
  <lastmod>2018-12-13T06:06:48-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4a/0000899243-18-030927</loc>
  <lastmod>2018-12-13T18:18:57-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4a/0000899243-18-030928</loc>
  <lastmod>2018-12-13T18:18:58-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-1/0001193125-19-157100</loc>
  <lastmod>2019-05-24T16:51:04-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-015088</loc>
  <lastmod>2019-05-29T19:19:33-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13da/0001193125-19-159860</loc>
  <lastmod>2019-05-30T06:09:34-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-1a/0001193125-19-169677</loc>
  <lastmod>2019-06-11T06:30:48-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-1a/0001193125-19-174178</loc>
  <lastmod>2019-06-17T06:13:01-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-1a/0001193125-19-179321</loc>
  <lastmod>2019-06-24T07:14:54-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-1a/0001193125-19-181551</loc>
  <lastmod>2019-06-26T06:04:42-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-a12b/0001193125-19-181980</loc>
  <lastmod>2019-06-26T09:02:44-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-1mef/0001193125-19-183137</loc>
  <lastmod>2019-06-26T21:25:10-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/effect/9999999995-19-001448</loc>
  <lastmod>2019-06-27T06:02:27-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-19-018448</loc>
  <lastmod>2019-06-27T18:07:49-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-19-018451</loc>
  <lastmod>2019-06-27T18:09:49-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-19-018452</loc>
  <lastmod>2019-06-27T18:09:49-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-19-018455</loc>
  <lastmod>2019-06-27T18:11:49-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-19-018454</loc>
  <lastmod>2019-06-27T18:11:49-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-19-018461</loc>
  <lastmod>2019-06-27T18:13:49-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-19-018459</loc>
  <lastmod>2019-06-27T18:13:49-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-19-018457</loc>
  <lastmod>2019-06-27T18:13:49-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-19-018463</loc>
  <lastmod>2019-06-27T18:15:49-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-19-018466</loc>
  <lastmod>2019-06-27T18:19:49-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-19-018467</loc>
  <lastmod>2019-06-27T18:21:49-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-19-018468</loc>
  <lastmod>2019-06-27T18:29:49-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000903423-19-000262</loc>
  <lastmod>2019-06-27T19:14:51-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/424b4/0001193125-19-186080</loc>
  <lastmod>2019-06-28T16:38:32-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000903423-19-000265</loc>
  <lastmod>2019-06-28T19:04:36-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000903423-19-000266</loc>
  <lastmod>2019-06-28T19:04:36-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-8/0001193125-19-187461</loc>
  <lastmod>2019-07-01T17:08:21-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-019140</loc>
  <lastmod>2019-07-03T16:14:49-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-019136</loc>
  <lastmod>2019-07-03T16:14:50-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-019137</loc>
  <lastmod>2019-07-03T16:14:52-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-019144</loc>
  <lastmod>2019-07-03T16:16:48-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-019138</loc>
  <lastmod>2019-07-03T16:16:49-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-019145</loc>
  <lastmod>2019-07-03T16:18:53-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-019151</loc>
  <lastmod>2019-07-03T16:20:50-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-019150</loc>
  <lastmod>2019-07-03T16:20:51-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-019173</loc>
  <lastmod>2019-07-03T16:34:54-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-19-189260</loc>
  <lastmod>2019-07-03T16:36:52-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13d/0000903423-19-000277</loc>
  <lastmod>2019-07-08T16:50:15-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-019337</loc>
  <lastmod>2019-07-08T21:29:27-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13da/0001193125-19-190741</loc>
  <lastmod>2019-07-09T06:07:46-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13d/0001140361-19-012746</loc>
  <lastmod>2019-07-10T17:08:43-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13g/0001193125-19-192463</loc>
  <lastmod>2019-07-11T17:03:22-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13da/0001193125-19-216833</loc>
  <lastmod>2019-08-08T16:29:14-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-q/0001564590-19-031927</loc>
  <lastmod>2019-08-14T06:38:35-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-19-243348</loc>
  <lastmod>2019-09-12T06:10:34-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-19-266824</loc>
  <lastmod>2019-10-11T17:04:19-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13da/0001193125-19-267356</loc>
  <lastmod>2019-10-15T09:30:36-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-q/0001564590-19-041986</loc>
  <lastmod>2019-11-08T06:14:02-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-19-027428</loc>
  <lastmod>2019-11-15T19:21:17-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-19-027430</loc>
  <lastmod>2019-11-15T19:22:27-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-027431</loc>
  <lastmod>2019-11-15T19:23:47-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-027434</loc>
  <lastmod>2019-11-15T19:26:37-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-19-295582</loc>
  <lastmod>2019-11-19T16:35:05-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-8/0001193125-19-296695</loc>
  <lastmod>2019-11-20T17:27:07-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-029344</loc>
  <lastmod>2019-12-16T20:58:49-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-19-029343</loc>
  <lastmod>2019-12-16T20:58:49-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-029347</loc>
  <lastmod>2019-12-16T21:03:09-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-029348</loc>
  <lastmod>2019-12-16T21:03:09-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-029353</loc>
  <lastmod>2019-12-16T21:06:29-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-029352</loc>
  <lastmod>2019-12-16T21:06:29-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-029354</loc>
  <lastmod>2019-12-16T21:08:49-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-029358</loc>
  <lastmod>2019-12-16T21:09:59-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-029357</loc>
  <lastmod>2019-12-16T21:09:59-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-19-315521</loc>
  <lastmod>2019-12-17T06:11:31-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-19-323511</loc>
  <lastmod>2019-12-26T16:36:09-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-19-030273</loc>
  <lastmod>2019-12-31T16:08:27-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0001140361-20-000245</loc>
  <lastmod>2020-01-03T18:10:55-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001140361-20-000250</loc>
  <lastmod>2020-01-03T18:14:25-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-000654</loc>
  <lastmod>2020-01-06T20:58:30-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-000659</loc>
  <lastmod>2020-01-06T21:18:32-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-000660</loc>
  <lastmod>2020-01-06T21:32:42-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-20-003038</loc>
  <lastmod>2020-01-07T16:25:09-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-000991</loc>
  <lastmod>2020-01-10T17:19:59-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-001340</loc>
  <lastmod>2020-01-16T19:19:22-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-003289</loc>
  <lastmod>2020-02-05T17:01:01-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-003303</loc>
  <lastmod>2020-02-05T17:09:11-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-003297</loc>
  <lastmod>2020-02-05T17:13:51-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-003696</loc>
  <lastmod>2020-02-07T17:50:29-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-004375</loc>
  <lastmod>2020-02-12T19:05:07-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-004549</loc>
  <lastmod>2020-02-13T20:49:50-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/5/0000899243-20-004555</loc>
  <lastmod>2020-02-13T20:59:31-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13g/0001104659-20-020805</loc>
  <lastmod>2020-02-14T08:23:10-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13g/0001193125-20-038115</loc>
  <lastmod>2020-02-14T16:10:04-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13ga/0001193125-20-038299</loc>
  <lastmod>2020-02-14T17:12:07-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/5a/0000899243-20-004685</loc>
  <lastmod>2020-02-14T17:49:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-20-004742</loc>
  <lastmod>2020-02-14T19:16:13-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-004747</loc>
  <lastmod>2020-02-14T19:24:14-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-004766</loc>
  <lastmod>2020-02-14T20:09:46-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-20-042081</loc>
  <lastmod>2020-02-19T18:33:02-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-20-058049</loc>
  <lastmod>2020-03-02T08:47:20-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-k/0001564590-20-008260</loc>
  <lastmod>2020-03-03T06:16:48-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-8/0001193125-20-060577</loc>
  <lastmod>2020-03-04T06:14:01-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-20-060890</loc>
  <lastmod>2020-03-04T07:23:02-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-006942</loc>
  <lastmod>2020-03-04T16:08:26-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-006945</loc>
  <lastmod>2020-03-04T16:12:55-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-006988</loc>
  <lastmod>2020-03-04T18:00:24-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-20-063716</loc>
  <lastmod>2020-03-06T06:34:20-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-20-067542</loc>
  <lastmod>2020-03-10T06:07:48-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/drs/0000950123-19-002230</loc>
  <lastmod>2020-03-14T18:45:35-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/drsa/0000950123-19-005586</loc>
  <lastmod>2020-03-22T22:30:01-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/drsa/0000950123-19-003351</loc>
  <lastmod>2020-03-22T22:30:08-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-20-083085</loc>
  <lastmod>2020-03-24T06:09:39-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-010119</loc>
  <lastmod>2020-04-03T16:13:12-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-010120</loc>
  <lastmod>2020-04-03T16:15:13-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-010122</loc>
  <lastmod>2020-04-03T16:15:25-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-010359</loc>
  <lastmod>2020-04-06T21:20:44-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-010392</loc>
  <lastmod>2020-04-07T16:09:16-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-010587</loc>
  <lastmod>2020-04-09T16:07:48-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-010631</loc>
  <lastmod>2020-04-10T08:28:37-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/def-14a/0001140361-20-009469</loc>
  <lastmod>2020-04-22T17:26:03-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/defa14a/0001193125-20-117295</loc>
  <lastmod>2020-04-23T16:50:02-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-011523</loc>
  <lastmod>2020-04-29T16:09:36-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-20-126364</loc>
  <lastmod>2020-04-29T16:50:42-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-011988</loc>
  <lastmod>2020-05-05T06:15:56-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-011989</loc>
  <lastmod>2020-05-05T06:17:31-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-012046</loc>
  <lastmod>2020-05-05T16:09:02-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-012192</loc>
  <lastmod>2020-05-06T20:24:27-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-012195</loc>
  <lastmod>2020-05-06T20:28:37-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-012196</loc>
  <lastmod>2020-05-06T20:31:42-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-20-141632</loc>
  <lastmod>2020-05-13T16:29:47-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-q/0001564590-20-025197</loc>
  <lastmod>2020-05-14T06:06:32-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-013832</loc>
  <lastmod>2020-05-21T16:10:09-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-013835</loc>
  <lastmod>2020-05-21T16:23:43-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-013844</loc>
  <lastmod>2020-05-21T16:30:51-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-013850</loc>
  <lastmod>2020-05-21T16:35:12-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-014325</loc>
  <lastmod>2020-05-27T17:00:38-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13da/0001140361-20-012844</loc>
  <lastmod>2020-06-01T17:15:30-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001140361-20-012852</loc>
  <lastmod>2020-06-01T17:21:02-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-015047</loc>
  <lastmod>2020-06-03T16:09:57-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-015045</loc>
  <lastmod>2020-06-03T16:10:01-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-015043</loc>
  <lastmod>2020-06-03T16:10:04-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-015042</loc>
  <lastmod>2020-06-03T16:10:14-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-015297</loc>
  <lastmod>2020-06-04T19:14:24-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-015301</loc>
  <lastmod>2020-06-04T19:20:55-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-015302</loc>
  <lastmod>2020-06-04T19:22:32-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-015304</loc>
  <lastmod>2020-06-04T19:23:13-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-015306</loc>
  <lastmod>2020-06-04T19:23:17-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-015308</loc>
  <lastmod>2020-06-04T19:28:40-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-015534</loc>
  <lastmod>2020-06-05T20:01:04-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-015537</loc>
  <lastmod>2020-06-05T20:01:08-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-015540</loc>
  <lastmod>2020-06-05T20:02:44-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-015541</loc>
  <lastmod>2020-06-05T20:07:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-20-163454</loc>
  <lastmod>2020-06-08T16:10:25-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-015951</loc>
  <lastmod>2020-06-10T16:09:36-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-015953</loc>
  <lastmod>2020-06-10T16:14:43-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-015957</loc>
  <lastmod>2020-06-10T16:14:54-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-20-177774</loc>
  <lastmod>2020-06-24T17:18:38-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-017663</loc>
  <lastmod>2020-06-25T16:40:29-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-20-017658</loc>
  <lastmod>2020-06-25T16:40:44-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-20-017660</loc>
  <lastmod>2020-06-25T16:41:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-20-017662</loc>
  <lastmod>2020-06-25T16:42:50-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-017667</loc>
  <lastmod>2020-06-25T16:48:32-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-017666</loc>
  <lastmod>2020-06-25T16:48:32-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-018288</loc>
  <lastmod>2020-07-02T16:30:29-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-018483</loc>
  <lastmod>2020-07-06T17:31:06-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-018485</loc>
  <lastmod>2020-07-06T17:32:20-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-018518</loc>
  <lastmod>2020-07-06T19:20:46-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-8/0001193125-20-188049</loc>
  <lastmod>2020-07-07T06:04:59-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-3asr/0001193125-20-188892</loc>
  <lastmod>2020-07-07T17:31:45-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-3asr/0001193125-20-201049</loc>
  <lastmod>2020-07-28T16:49:22-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-021505</loc>
  <lastmod>2020-08-05T18:07:32-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-021550</loc>
  <lastmod>2020-08-05T18:51:27-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-021557</loc>
  <lastmod>2020-08-05T19:00:56-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-20-215681</loc>
  <lastmod>2020-08-11T08:06:03-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-q/0001564590-20-039358</loc>
  <lastmod>2020-08-11T17:21:34-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-022785</loc>
  <lastmod>2020-08-18T19:00:55-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-022786</loc>
  <lastmod>2020-08-18T19:00:58-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-022790</loc>
  <lastmod>2020-08-18T19:04:10-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-022791</loc>
  <lastmod>2020-08-18T19:04:10-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-022792</loc>
  <lastmod>2020-08-18T19:05:44-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-022794</loc>
  <lastmod>2020-08-18T19:12:15-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-023892</loc>
  <lastmod>2020-09-02T16:19:09-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-024078</loc>
  <lastmod>2020-09-03T16:09:54-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-025095</loc>
  <lastmod>2020-09-15T16:08:37-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-025366</loc>
  <lastmod>2020-09-16T18:41:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-025693</loc>
  <lastmod>2020-09-18T16:06:44-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-025961</loc>
  <lastmod>2020-09-22T19:08:47-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-025962</loc>
  <lastmod>2020-09-22T19:10:23-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-20-257161</loc>
  <lastmod>2020-09-29T07:04:04-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-026476</loc>
  <lastmod>2020-09-29T19:05:15-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-026658</loc>
  <lastmod>2020-10-01T16:09:45-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-026978</loc>
  <lastmod>2020-10-02T20:02:03-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-027232</loc>
  <lastmod>2020-10-05T16:06:45-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/425/0001193125-20-263996</loc>
  <lastmod>2020-10-05T17:19:14-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-20-263994</loc>
  <lastmod>2020-10-05T17:21:59-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13da/0001193125-20-264026</loc>
  <lastmod>2020-10-05T17:33:20-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/425/0001193125-20-264235</loc>
  <lastmod>2020-10-06T06:05:45-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13da/0001140361-20-022590</loc>
  <lastmod>2020-10-06T16:47:07-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/425/0001193125-20-264839</loc>
  <lastmod>2020-10-06T17:19:58-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-20-264837</loc>
  <lastmod>2020-10-06T17:20:02-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13d/0001193125-20-270273</loc>
  <lastmod>2020-10-15T16:19:35-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-028659</loc>
  <lastmod>2020-10-19T21:17:16-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-20-275507</loc>
  <lastmod>2020-10-23T16:33:08-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-030214</loc>
  <lastmod>2020-11-03T16:12:59-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-20-286266</loc>
  <lastmod>2020-11-05T08:03:05-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-q/0001564590-20-051460</loc>
  <lastmod>2020-11-05T17:12:45-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-20-287485</loc>
  <lastmod>2020-11-06T08:41:18-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-4/0001193125-20-288071</loc>
  <lastmod>2020-11-06T17:08:15-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-030623</loc>
  <lastmod>2020-11-09T16:20:38-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-031267</loc>
  <lastmod>2020-11-17T16:09:12-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-031548</loc>
  <lastmod>2020-11-18T19:43:17-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-031555</loc>
  <lastmod>2020-11-18T19:46:33-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-031549</loc>
  <lastmod>2020-11-18T19:46:33-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-031557</loc>
  <lastmod>2020-11-18T19:46:36-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-031571</loc>
  <lastmod>2020-11-18T19:55:31-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-031586</loc>
  <lastmod>2020-11-18T20:48:21-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-032234</loc>
  <lastmod>2020-11-25T22:01:01-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-032503</loc>
  <lastmod>2020-12-02T16:07:33-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-032507</loc>
  <lastmod>2020-12-02T16:19:46-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-4a/0001193125-20-315363</loc>
  <lastmod>2020-12-11T07:14:33-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/424b3/0001193125-20-317635</loc>
  <lastmod>2020-12-15T09:25:45-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/defm14a/0001193125-20-317638</loc>
  <lastmod>2020-12-15T09:30:06-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/effect/9999999995-20-003530</loc>
  <lastmod>2020-12-16T06:13:38-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-034282</loc>
  <lastmod>2020-12-17T16:09:00-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-034284</loc>
  <lastmod>2020-12-17T16:09:05-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-034280</loc>
  <lastmod>2020-12-17T16:10:05-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-034688</loc>
  <lastmod>2020-12-21T16:07:00-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-035011</loc>
  <lastmod>2020-12-23T17:39:48-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-20-035444</loc>
  <lastmod>2020-12-29T21:16:43-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/425/0001193125-21-001014</loc>
  <lastmod>2021-01-04T16:34:20-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-001019</loc>
  <lastmod>2021-01-04T16:34:26-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/425/0001193125-21-006803</loc>
  <lastmod>2021-01-12T07:45:40-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-006802</loc>
  <lastmod>2021-01-12T07:48:58-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/425/0001193125-21-008184</loc>
  <lastmod>2021-01-13T16:45:15-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-012440</loc>
  <lastmod>2021-01-20T16:22:58-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-8/0001193125-21-016252</loc>
  <lastmod>2021-01-25T16:20:35-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-8/0001193125-21-016258</loc>
  <lastmod>2021-01-25T16:22:37-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-017108</loc>
  <lastmod>2021-01-26T08:49:59-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13da/0001193125-21-017128</loc>
  <lastmod>2021-01-26T09:03:42-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-003286</loc>
  <lastmod>2021-01-26T16:06:56-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13da/0001193125-21-017733</loc>
  <lastmod>2021-01-26T16:24:55-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-017810</loc>
  <lastmod>2021-01-26T17:01:03-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-003676</loc>
  <lastmod>2021-01-28T20:43:36-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-021591</loc>
  <lastmod>2021-01-29T07:09:21-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13g/0000834237-21-007395</loc>
  <lastmod>2021-02-05T07:54:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13g/0001104659-21-017620</loc>
  <lastmod>2021-02-10T10:48:16-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/424b7/0001193125-21-038747</loc>
  <lastmod>2021-02-11T17:19:01-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/5/0000899243-21-006293</loc>
  <lastmod>2021-02-12T16:18:43-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-006432</loc>
  <lastmod>2021-02-12T20:47:44-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-006433</loc>
  <lastmod>2021-02-12T20:54:00-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13ga/0001104659-21-022257</loc>
  <lastmod>2021-02-16T06:33:22-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13ga/0001193125-21-044721</loc>
  <lastmod>2021-02-16T15:38:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13ga/0001193125-21-045151</loc>
  <lastmod>2021-02-16T17:15:49-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/424b7/0001193125-21-045260</loc>
  <lastmod>2021-02-16T17:35:57-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-046513</loc>
  <lastmod>2021-02-17T16:19:40-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13da/0001140361-21-005265</loc>
  <lastmod>2021-02-17T17:30:43-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001140361-21-005267</loc>
  <lastmod>2021-02-17T17:39:50-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-007172</loc>
  <lastmod>2021-02-18T18:23:31-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-007211</loc>
  <lastmod>2021-02-18T19:47:28-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-007227</loc>
  <lastmod>2021-02-18T20:36:53-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-k/0001564590-21-008969</loc>
  <lastmod>2021-02-25T17:36:46-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-058156</loc>
  <lastmod>2021-02-26T06:40:28-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-009369</loc>
  <lastmod>2021-03-03T16:11:02-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-101373</loc>
  <lastmod>2021-03-31T07:39:27-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-117878</loc>
  <lastmod>2021-04-15T16:57:38-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/def-14a/0001193125-21-145491</loc>
  <lastmod>2021-04-30T17:07:27-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-q/0001564590-21-025064</loc>
  <lastmod>2021-05-06T16:43:06-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-157729</loc>
  <lastmod>2021-05-11T17:09:37-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-162215</loc>
  <lastmod>2021-05-14T17:33:35-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-019798</loc>
  <lastmod>2021-05-18T18:31:41-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-019799</loc>
  <lastmod>2021-05-18T18:33:57-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-177835</loc>
  <lastmod>2021-06-01T07:44:22-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-196269</loc>
  <lastmod>2021-06-22T16:34:40-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-025359</loc>
  <lastmod>2021-06-22T18:48:59-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-025362</loc>
  <lastmod>2021-06-22T18:51:08-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-025367</loc>
  <lastmod>2021-06-22T18:52:49-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-025381</loc>
  <lastmod>2021-06-22T19:05:40-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-025387</loc>
  <lastmod>2021-06-22T19:11:38-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-025398</loc>
  <lastmod>2021-06-22T19:20:17-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-025397</loc>
  <lastmod>2021-06-22T19:20:18-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-025402</loc>
  <lastmod>2021-06-22T19:24:03-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-025410</loc>
  <lastmod>2021-06-22T19:41:15-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-025414</loc>
  <lastmod>2021-06-22T20:13:24-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-q/0001564590-21-041676</loc>
  <lastmod>2021-08-05T16:52:26-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-031954</loc>
  <lastmod>2021-08-06T18:12:33-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-246183</loc>
  <lastmod>2021-08-13T16:51:34-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/corresp/0001193125-20-288076</loc>
  <lastmod>2021-08-15T22:37:57-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/upload/0000000000-20-010881</loc>
  <lastmod>2021-08-15T22:39:44-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/corresp/0001193125-20-315370</loc>
  <lastmod>2021-08-15T22:39:52-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-033438</loc>
  <lastmod>2021-08-18T16:09:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-033443</loc>
  <lastmod>2021-08-18T16:14:07-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-254149</loc>
  <lastmod>2021-08-24T06:03:20-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-21-034257</loc>
  <lastmod>2021-08-26T16:34:33-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-21-034258</loc>
  <lastmod>2021-08-26T16:35:31-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-21-034267</loc>
  <lastmod>2021-08-26T16:38:54-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-034290</loc>
  <lastmod>2021-08-26T17:16:43-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-034291</loc>
  <lastmod>2021-08-26T17:16:58-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-034292</loc>
  <lastmod>2021-08-26T17:18:59-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/corresp/0001193125-19-180056</loc>
  <lastmod>2021-10-02T12:16:58-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/corresp/0001193125-19-157106</loc>
  <lastmod>2021-10-02T12:24:40-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/corresp/0001193125-19-180050</loc>
  <lastmod>2021-10-02T12:56:32-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/upload/0000000000-19-007796</loc>
  <lastmod>2021-10-02T15:35:11-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/upload/0000000000-19-004853</loc>
  <lastmod>2021-10-02T16:28:43-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/upload/0000000000-19-010263</loc>
  <lastmod>2021-10-02T18:30:40-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/upload/0000000000-19-008853</loc>
  <lastmod>2021-10-02T18:32:31-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/corresp/0001193125-19-169684</loc>
  <lastmod>2021-10-02T20:43:08-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/upload/0000000000-19-009165</loc>
  <lastmod>2021-10-03T01:59:51-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/corresp/0001193125-19-169687</loc>
  <lastmod>2021-10-03T02:15:01-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/corresp/0001193125-19-181565</loc>
  <lastmod>2021-10-03T03:24:01-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-307134</loc>
  <lastmod>2021-10-26T06:10:54-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000899243-21-041667</loc>
  <lastmod>2021-10-26T21:24:39-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-041672</loc>
  <lastmod>2021-10-26T21:24:40-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/pre-14a/0001193125-21-313515</loc>
  <lastmod>2021-10-29T17:07:42-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-319331</loc>
  <lastmod>2021-11-04T07:38:57-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-q/0000950170-21-003080</loc>
  <lastmod>2021-11-04T16:31:02-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/def-14a/0001193125-21-323214</loc>
  <lastmod>2021-11-08T17:24:12-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-333214</loc>
  <lastmod>2021-11-18T08:02:44-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-045259</loc>
  <lastmod>2021-11-18T16:06:47-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-045260</loc>
  <lastmod>2021-11-18T16:07:29-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-047030</loc>
  <lastmod>2021-12-06T21:06:14-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-047032</loc>
  <lastmod>2021-12-06T21:06:15-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-047180</loc>
  <lastmod>2021-12-07T18:07:18-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-047188</loc>
  <lastmod>2021-12-07T18:18:11-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-358518</loc>
  <lastmod>2021-12-16T06:43:33-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-21-366669</loc>
  <lastmod>2021-12-27T07:07:32-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-21-050130</loc>
  <lastmod>2021-12-30T20:24:30-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-22-000180</loc>
  <lastmod>2022-01-03T21:14:31-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-22-000176</loc>
  <lastmod>2022-01-03T21:15:13-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-22-000174</loc>
  <lastmod>2022-01-03T21:15:14-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-22-000188</loc>
  <lastmod>2022-01-03T21:16:06-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-22-000193</loc>
  <lastmod>2022-01-03T21:16:43-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-22-001169</loc>
  <lastmod>2022-01-06T16:09:09-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13ga/0000834237-22-006373</loc>
  <lastmod>2022-02-03T16:47:06-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13ga/0001104659-22-016682</loc>
  <lastmod>2022-02-09T15:37:44-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13ga/0001193125-22-042014</loc>
  <lastmod>2022-02-14T18:03:12-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13ga/0001193125-22-042606</loc>
  <lastmod>2022-02-15T06:37:33-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-22-007031</loc>
  <lastmod>2022-02-18T16:37:26-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-22-007030</loc>
  <lastmod>2022-02-18T16:37:26-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-22-051102</loc>
  <lastmod>2022-02-24T07:39:48-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-k/0000950170-22-002030</loc>
  <lastmod>2022-02-25T08:14:15-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-8/0001193125-22-053534</loc>
  <lastmod>2022-02-25T09:25:23-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-22-011086</loc>
  <lastmod>2022-03-15T17:36:05-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-22-011088</loc>
  <lastmod>2022-03-15T17:39:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-22-011246</loc>
  <lastmod>2022-03-16T16:48:09-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-22-011386</loc>
  <lastmod>2022-03-17T16:10:09-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-22-011592</loc>
  <lastmod>2022-03-18T16:26:23-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-22-011594</loc>
  <lastmod>2022-03-18T16:27:43-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/def-14a/0001193125-22-133557</loc>
  <lastmod>2022-04-29T16:09:13-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/defa14a/0001193125-22-133655</loc>
  <lastmod>2022-04-29T16:17:33-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-q/0000950170-22-007874</loc>
  <lastmod>2022-05-05T17:21:39-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-22-146467</loc>
  <lastmod>2022-05-10T17:26:52-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-22-150167</loc>
  <lastmod>2022-05-13T16:39:32-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-22-154023</loc>
  <lastmod>2022-05-18T16:04:01-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-22-018594</loc>
  <lastmod>2022-05-18T16:08:34-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-22-018591</loc>
  <lastmod>2022-05-18T16:08:50-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-22-018595</loc>
  <lastmod>2022-05-18T16:11:27-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000899243-22-018590</loc>
  <lastmod>2022-05-18T16:17:45-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-039225</loc>
  <lastmod>2022-06-24T16:26:41-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-039232</loc>
  <lastmod>2022-06-24T16:28:38-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-039238</loc>
  <lastmod>2022-06-24T16:29:26-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-039234</loc>
  <lastmod>2022-06-24T16:29:27-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-039241</loc>
  <lastmod>2022-06-24T16:30:56-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-039243</loc>
  <lastmod>2022-06-24T16:31:43-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-22-181550</loc>
  <lastmod>2022-06-24T16:32:20-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-039259</loc>
  <lastmod>2022-06-24T16:35:40-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-039249</loc>
  <lastmod>2022-06-24T16:35:41-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-039256</loc>
  <lastmod>2022-06-24T16:35:41-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-039262</loc>
  <lastmod>2022-06-24T16:36:03-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-039264</loc>
  <lastmod>2022-06-24T16:37:52-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-039268</loc>
  <lastmod>2022-06-24T16:39:48-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-039265</loc>
  <lastmod>2022-06-24T16:40:00-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-039270</loc>
  <lastmod>2022-06-24T16:40:45-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-22-201502</loc>
  <lastmod>2022-07-26T08:02:52-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-22-212597</loc>
  <lastmod>2022-08-04T16:45:43-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-q/0000950170-22-014824</loc>
  <lastmod>2022-08-04T16:51:37-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-046731</loc>
  <lastmod>2022-08-18T18:36:26-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-046731</loc>
  <lastmod>2022-08-18T18:36:26-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-046735</loc>
  <lastmod>2022-08-18T18:40:19-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-046733</loc>
  <lastmod>2022-08-18T18:40:24-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-046739</loc>
  <lastmod>2022-08-18T18:44:48-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-22-250165</loc>
  <lastmod>2022-09-23T16:22:06-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-q/0000950170-22-021936</loc>
  <lastmod>2022-11-03T16:38:09-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-22-277008</loc>
  <lastmod>2022-11-03T17:09:37-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-057982</loc>
  <lastmod>2022-11-18T18:40:14-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-057984</loc>
  <lastmod>2022-11-18T18:42:26-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-057983</loc>
  <lastmod>2022-11-18T18:42:31-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-057985</loc>
  <lastmod>2022-11-18T18:46:58-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-22-299475</loc>
  <lastmod>2022-12-06T17:06:07-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-22-062377</loc>
  <lastmod>2022-12-21T20:05:38-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-002488</loc>
  <lastmod>2023-01-06T20:46:50-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-002486</loc>
  <lastmod>2023-01-06T20:47:25-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13ga/0001306550-23-005792</loc>
  <lastmod>2023-02-01T06:21:14-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-8/0001193125-23-025671</loc>
  <lastmod>2023-02-06T16:45:32-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-007376</loc>
  <lastmod>2023-02-06T19:33:02-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-007381</loc>
  <lastmod>2023-02-06T19:56:31-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13g/0000093751-23-000350</loc>
  <lastmod>2023-02-08T10:33:17-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13ga/0001104659-23-015498</loc>
  <lastmod>2023-02-09T11:18:43-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13ga/0001193125-23-039173</loc>
  <lastmod>2023-02-14T16:29:54-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-009272</loc>
  <lastmod>2023-02-14T17:30:08-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-009280</loc>
  <lastmod>2023-02-14T17:30:56-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-011447</loc>
  <lastmod>2023-02-21T20:18:14-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-011452</loc>
  <lastmod>2023-02-21T20:28:02-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-011457</loc>
  <lastmod>2023-02-21T20:28:02-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-011450</loc>
  <lastmod>2023-02-21T20:28:03-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-011455</loc>
  <lastmod>2023-02-21T20:28:06-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-23-045663</loc>
  <lastmod>2023-02-23T07:53:07-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-k/0000950170-23-004145</loc>
  <lastmod>2023-02-23T17:50:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-012392</loc>
  <lastmod>2023-02-23T20:05:38-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0001209191-23-013954</loc>
  <lastmod>2023-02-28T22:02:06-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-016059</loc>
  <lastmod>2023-03-03T20:08:59-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-016060</loc>
  <lastmod>2023-03-03T20:18:25-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-23-060828</loc>
  <lastmod>2023-03-06T09:13:55-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/424b5/0001193125-23-061614</loc>
  <lastmod>2023-03-06T17:31:02-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/424b5/0001193125-23-065456</loc>
  <lastmod>2023-03-09T09:03:17-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-23-065459</loc>
  <lastmod>2023-03-09T09:03:56-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-23-000084</loc>
  <lastmod>2023-04-05T16:37:21-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-023803</loc>
  <lastmod>2023-04-07T16:42:38-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-023808</loc>
  <lastmod>2023-04-07T16:45:43-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/def-14a/0001193125-23-127256</loc>
  <lastmod>2023-04-28T16:43:29-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/defa14a/0001193125-23-127322</loc>
  <lastmod>2023-04-28T16:51:12-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/ars/0001193125-23-127377</loc>
  <lastmod>2023-04-28T18:12:36-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-23-000357</loc>
  <lastmod>2023-05-03T16:36:19-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-23-135073</loc>
  <lastmod>2023-05-04T07:48:11-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-q/0000950170-23-017812</loc>
  <lastmod>2023-05-04T16:10:06-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-3asr/0001193125-23-136048</loc>
  <lastmod>2023-05-04T16:59:03-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001193125-23-136095</loc>
  <lastmod>2023-05-04T17:22:31-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-8/0001193125-23-136099</loc>
  <lastmod>2023-05-04T17:24:35-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-027626</loc>
  <lastmod>2023-05-05T16:05:48-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-027630</loc>
  <lastmod>2023-05-05T16:07:37-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-23-000700</loc>
  <lastmod>2023-05-17T16:49:01-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-23-000702</loc>
  <lastmod>2023-05-17T16:49:51-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-030581</loc>
  <lastmod>2023-05-18T16:05:51-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-030599</loc>
  <lastmod>2023-05-18T16:09:20-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-030593</loc>
  <lastmod>2023-05-18T16:09:24-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001140361-23-030932</loc>
  <lastmod>2023-06-22T16:07:17-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-039342</loc>
  <lastmod>2023-06-23T16:16:34-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-039352</loc>
  <lastmod>2023-06-23T16:19:30-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-039347</loc>
  <lastmod>2023-06-23T16:19:30-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-039361</loc>
  <lastmod>2023-06-23T16:19:38-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-039375</loc>
  <lastmod>2023-06-23T16:21:55-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-039369</loc>
  <lastmod>2023-06-23T16:22:46-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-039387</loc>
  <lastmod>2023-06-23T16:24:24-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-039380</loc>
  <lastmod>2023-06-23T16:24:24-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-039385</loc>
  <lastmod>2023-06-23T16:24:32-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-039393</loc>
  <lastmod>2023-06-23T16:27:23-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-039391</loc>
  <lastmod>2023-06-23T16:27:23-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-039396</loc>
  <lastmod>2023-06-23T16:30:58-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001140361-23-034684</loc>
  <lastmod>2023-07-17T07:27:06-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/ct-order/9999999997-23-003562</loc>
  <lastmod>2023-07-18T16:24:25-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001140361-23-035097</loc>
  <lastmod>2023-07-18T21:39:15-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001140361-23-035288</loc>
  <lastmod>2023-07-19T21:39:52-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13da/0001140361-23-035291</loc>
  <lastmod>2023-07-20T06:09:23-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-3asr/0001140361-23-036235</loc>
  <lastmod>2023-07-26T16:09:17-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0000950170-23-037590</loc>
  <lastmod>2023-08-03T07:35:10-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-q/0000950170-23-037977</loc>
  <lastmod>2023-08-03T16:17:51-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-23-003217</loc>
  <lastmod>2023-08-17T16:13:05-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-23-003218</loc>
  <lastmod>2023-08-17T16:13:44-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-046512</loc>
  <lastmod>2023-08-18T16:02:49-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-046511</loc>
  <lastmod>2023-08-18T16:04:20-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-046514</loc>
  <lastmod>2023-08-18T16:05:04-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-23-003687</loc>
  <lastmod>2023-09-05T16:15:51-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-048595</loc>
  <lastmod>2023-09-07T16:04:28-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0000950170-23-049683</loc>
  <lastmod>2023-09-25T16:05:19-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0000950170-23-057745</loc>
  <lastmod>2023-11-02T07:34:41-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-q/0000950170-23-058255</loc>
  <lastmod>2023-11-02T16:43:40-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-3asr/0001140361-23-051194</loc>
  <lastmod>2023-11-02T17:02:31-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-23-004995</loc>
  <lastmod>2023-11-15T16:05:45-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-055717</loc>
  <lastmod>2023-11-17T16:14:57-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-23-005156</loc>
  <lastmod>2023-11-17T16:28:14-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-23-005157</loc>
  <lastmod>2023-11-17T16:28:59-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-056012</loc>
  <lastmod>2023-11-20T16:02:35-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-056011</loc>
  <lastmod>2023-11-20T16:04:16-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-056015</loc>
  <lastmod>2023-11-20T16:04:16-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13da/0001140361-23-054445</loc>
  <lastmod>2023-11-22T16:16:26-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-23-005559</loc>
  <lastmod>2023-12-01T16:22:07-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-057374</loc>
  <lastmod>2023-12-05T16:03:40-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-23-006122</loc>
  <lastmod>2023-12-15T16:15:26-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-23-006232</loc>
  <lastmod>2023-12-18T16:16:46-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-059101</loc>
  <lastmod>2023-12-19T16:06:15-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-059324</loc>
  <lastmod>2023-12-20T16:04:25-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0002002698-23-000189</loc>
  <lastmod>2023-12-26T17:36:17-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001209191-23-059885</loc>
  <lastmod>2023-12-28T16:05:18-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-8/0001140361-24-001006</loc>
  <lastmod>2024-01-05T16:08:38-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001140361-24-001358</loc>
  <lastmod>2024-01-08T17:18:12-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-24-000288</loc>
  <lastmod>2024-01-16T16:06:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001140361-24-002636</loc>
  <lastmod>2024-01-18T07:32:29-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-005380</loc>
  <lastmod>2024-01-18T16:14:14-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13ga/0000093751-24-000091</loc>
  <lastmod>2024-01-23T10:18:22-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13ga/0001086364-24-005626</loc>
  <lastmod>2024-01-29T17:28:18-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-014523</loc>
  <lastmod>2024-02-13T16:03:16-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/5/0000950170-24-014537</loc>
  <lastmod>2024-02-13T16:08:42-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13ga/0001104659-24-020469</loc>
  <lastmod>2024-02-13T17:03:04-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-24-000956</loc>
  <lastmod>2024-02-15T16:08:22-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13ga/0001140361-24-008424</loc>
  <lastmod>2024-02-16T19:18:44-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-017081</loc>
  <lastmod>2024-02-20T16:05:57-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-017891</loc>
  <lastmod>2024-02-21T16:07:44-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-017895</loc>
  <lastmod>2024-02-21T16:07:44-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-017894</loc>
  <lastmod>2024-02-21T16:08:28-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0000950170-24-018431</loc>
  <lastmod>2024-02-22T07:33:53-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-k/0000950170-24-018811</loc>
  <lastmod>2024-02-22T16:32:29-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001140361-24-010920</loc>
  <lastmod>2024-03-04T07:02:56-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/424b5/0001140361-24-011117</loc>
  <lastmod>2024-03-04T17:26:03-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-025839</loc>
  <lastmod>2024-03-05T16:04:03-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001140361-24-011766</loc>
  <lastmod>2024-03-06T17:15:48-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/424b5/0001140361-24-011764</loc>
  <lastmod>2024-03-06T17:17:57-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-031431</loc>
  <lastmod>2024-03-14T16:02:25-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-031433</loc>
  <lastmod>2024-03-14T16:04:22-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/def-14a/0001140361-24-022023</loc>
  <lastmod>2024-04-25T16:05:15-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/defa14a/0001140361-24-022031</loc>
  <lastmod>2024-04-25T16:10:02-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/ars/0001140361-24-022037</loc>
  <lastmod>2024-04-25T16:11:26-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0000950170-24-051573</loc>
  <lastmod>2024-05-02T07:33:09-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-q/0000950170-24-052165</loc>
  <lastmod>2024-05-02T16:29:27-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-061638</loc>
  <lastmod>2024-05-17T16:11:43-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-061646</loc>
  <lastmod>2024-05-17T16:13:49-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-24-004353</loc>
  <lastmod>2024-06-03T17:00:48-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-069401</loc>
  <lastmod>2024-06-05T16:56:30-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001140361-24-029050</loc>
  <lastmod>2024-06-06T06:09:15-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001140361-24-031087</loc>
  <lastmod>2024-06-24T16:03:08-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-077437</loc>
  <lastmod>2024-06-25T17:37:37-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-077441</loc>
  <lastmod>2024-06-25T17:39:55-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-077440</loc>
  <lastmod>2024-06-25T17:39:55-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-077442</loc>
  <lastmod>2024-06-25T17:39:55-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-077446</loc>
  <lastmod>2024-06-25T17:43:51-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-077448</loc>
  <lastmod>2024-06-25T17:43:51-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-077450</loc>
  <lastmod>2024-06-25T17:43:51-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-077443</loc>
  <lastmod>2024-06-25T17:43:51-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-077452</loc>
  <lastmod>2024-06-25T17:43:51-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-077445</loc>
  <lastmod>2024-06-25T17:43:51-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-077444</loc>
  <lastmod>2024-06-25T17:43:51-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-077447</loc>
  <lastmod>2024-06-25T17:43:52-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-077455</loc>
  <lastmod>2024-06-25T17:46:12-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001140361-24-033856</loc>
  <lastmod>2024-07-23T16:15:02-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000950170-24-087461</loc>
  <lastmod>2024-07-29T20:24:33-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0000950170-24-088952</loc>
  <lastmod>2024-08-01T07:33:38-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-q/0000950170-24-089326</loc>
  <lastmod>2024-08-01T16:29:45-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/s-8/0001140361-24-035364</loc>
  <lastmod>2024-08-01T17:07:09-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-094117</loc>
  <lastmod>2024-08-08T16:43:44-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-24-006220</loc>
  <lastmod>2024-08-19T16:28:49-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-24-006225</loc>
  <lastmod>2024-08-19T16:32:43-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-099267</loc>
  <lastmod>2024-08-20T18:27:15-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-099269</loc>
  <lastmod>2024-08-20T18:30:44-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-099275</loc>
  <lastmod>2024-08-20T18:35:04-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13da/0001140361-24-037981</loc>
  <lastmod>2024-08-20T20:53:39-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001140361-24-037974</loc>
  <lastmod>2024-08-21T06:09:40-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001140361-24-040755</loc>
  <lastmod>2024-09-11T06:11:05-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001140361-24-041079</loc>
  <lastmod>2024-09-13T17:05:51-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13da/0001140361-24-041327</loc>
  <lastmod>2024-09-17T18:45:35-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001140361-24-041329</loc>
  <lastmod>2024-09-17T18:48:05-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13ga/0002012383-24-001573</loc>
  <lastmod>2024-10-22T18:08:12-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13da/0000905148-24-002952</loc>
  <lastmod>2024-11-06T17:05:15-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0000950170-24-124576</loc>
  <lastmod>2024-11-12T09:32:53-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-q/0000950170-24-124577</loc>
  <lastmod>2024-11-12T09:35:04-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/sc-13ga/0002012383-24-004337</loc>
  <lastmod>2024-11-12T11:48:18-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-24-008805</loc>
  <lastmod>2024-11-19T16:25:43-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-24-008807</loc>
  <lastmod>2024-11-19T16:29:50-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-128888</loc>
  <lastmod>2024-11-19T18:09:39-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-128903</loc>
  <lastmod>2024-11-19T18:16:44-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-128910</loc>
  <lastmod>2024-11-19T18:18:41-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-129452</loc>
  <lastmod>2024-11-20T20:03:10-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-129455</loc>
  <lastmod>2024-11-20T20:07:25-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001140361-24-047704</loc>
  <lastmod>2024-11-25T06:18:36-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-135984</loc>
  <lastmod>2024-12-12T19:08:23-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-135982</loc>
  <lastmod>2024-12-12T19:08:34-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-135983</loc>
  <lastmod>2024-12-12T19:08:34-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-140871</loc>
  <lastmod>2024-12-27T19:12:51-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-140874</loc>
  <lastmod>2024-12-27T19:27:42-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-24-141676</loc>
  <lastmod>2024-12-31T17:57:33-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4a/0000950170-25-003541</loc>
  <lastmod>2025-01-08T17:50:00-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001140361-25-000943</loc>
  <lastmod>2025-01-13T16:58:52-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-25-000449</loc>
  <lastmod>2025-01-28T16:19:21-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-25-000450</loc>
  <lastmod>2025-01-28T16:19:48-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-25-011239</loc>
  <lastmod>2025-01-30T18:32:08-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-25-011242</loc>
  <lastmod>2025-01-30T18:32:15-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000905148-25-000306</loc>
  <lastmod>2025-01-31T19:23:50-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/0000905148-25-000308</loc>
  <lastmod>2025-01-31T19:31:22-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0000905148-25-000307</loc>
  <lastmod>2025-01-31T19:31:22-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/0000950170-25-020045</loc>
  <lastmod>2025-02-13T17:25:15-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-25-001040</loc>
  <lastmod>2025-02-19T16:33:13-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-25-001041</loc>
  <lastmod>2025-02-19T16:33:13-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-25-023625</loc>
  <lastmod>2025-02-19T20:52:13-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-25-023630</loc>
  <lastmod>2025-02-19T21:00:28-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-25-023632</loc>
  <lastmod>2025-02-19T21:00:28-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0000950170-25-023741</loc>
  <lastmod>2025-02-20T07:38:01-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/10-k/0000950170-25-024119</loc>
  <lastmod>2025-02-20T16:05:30-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-25-001234</loc>
  <lastmod>2025-02-25T16:35:42-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-25-001237</loc>
  <lastmod>2025-02-25T16:36:27-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-25-029228</loc>
  <lastmod>2025-02-27T17:14:42-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-25-029262</loc>
  <lastmod>2025-02-27T17:42:41-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/3/0000950170-25-029402</loc>
  <lastmod>2025-02-27T20:29:06-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/8-k/0001140361-25-006524</loc>
  <lastmod>2025-02-28T16:15:20-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001140361-25-007262</loc>
  <lastmod>2025-03-05T21:12:54-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/144/0001950047-25-001613</loc>
  <lastmod>2025-03-06T16:09:40-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0001140361-25-007699</loc>
  <lastmod>2025-03-07T18:12:57-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/0001140361-25-007701</loc>
  <lastmod>2025-03-07T18:20:14-05:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/4/0000950170-25-036420</loc>
  <lastmod>2025-03-10T16:46:01-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/sec-filings/sec-filing/0000905148-25-000909</loc>
  <lastmod>2025-03-12T16:28:48-04:00</lastmod>
  <priority>0.4</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/board-member/charles-homcy</loc>
  <lastmod>2022-06-10T15:35:51-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/board-member/ali-satvat</loc>
  <lastmod>2022-06-10T15:47:17-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/board-member/neil-kumar</loc>
  <lastmod>2022-06-10T15:49:15-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/management/brian-c-stephenson-phd-cfa</loc>
  <lastmod>2021-05-14T11:17:16-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/management/uma-sinha-phd</loc>
  <lastmod>2019-05-13T15:39:58-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/management/frank-mccormick-phd-frs-dsc-hon</loc>
  <lastmod>2019-05-13T15:41:46-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/management/cameron-turtle-d-phil</loc>
  <lastmod>2021-05-24T11:51:44-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/board-member/eric-aguiar-md</loc>
  <lastmod>2022-06-10T15:45:31-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/board-member/james-c-momtazee</loc>
  <lastmod>2022-06-10T15:46:16-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/analyst/george-farmer</loc>
  <lastmod>2024-05-23T16:17:36-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/analyst/paul-choi</loc>
  <lastmod>2020-02-06T17:02:08-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/analyst/anupam-rama</loc>
  <lastmod>2020-02-06T17:02:14-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/analyst/mani-foroohar</loc>
  <lastmod>2020-02-06T17:02:42-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/analyst/salim-syed</loc>
  <lastmod>2020-03-16T19:51:01-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/board-member/jennifer-cook</loc>
  <lastmod>2022-06-10T15:44:41-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/board-member/ronald-j-daniels</loc>
  <lastmod>2022-06-10T15:43:55-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/management/yi-ching-yau</loc>
  <lastmod>2020-04-08T14:57:45-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/board-member/randy-scott-phd</loc>
  <lastmod>2022-07-28T09:33:56-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/board-member/andrew-lo-phd</loc>
  <lastmod>2022-06-10T15:43:03-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/analyst/geoff-meacham</loc>
  <lastmod>2024-05-23T16:16:43-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/management/matthew-outten-mba-alm-cpc</loc>
  <lastmod>2021-05-13T14:28:03-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/board-member/fred-hassan</loc>
  <lastmod>2022-06-10T15:40:47-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/board-member/andrea-ellis</loc>
  <lastmod>2024-07-29T16:12:58-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/board-member/douglas-dachille</loc>
  <lastmod>2022-06-10T15:48:12-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/analyst/eliana-merle</loc>
  <lastmod>2021-10-12T21:05:31-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/board-member/hannah-valantine-md</loc>
  <lastmod>2022-06-10T15:50:17-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/management/adora-ndu-pharmd-jd</loc>
  <lastmod>2022-02-16T08:36:54-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/management/thomas-trimarchi-phd</loc>
  <lastmod>2022-02-16T08:37:40-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/analyst/tyler-van-buren-0</loc>
  <lastmod>2023-03-03T11:35:13-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/analyst/josh</loc>
  <lastmod>2023-11-09T08:54:25-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/board-member</loc>
  <lastmod>2023-10-26T20:54:40-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/analyst/david-lebowitz</loc>
  <lastmod>2023-11-09T09:00:40-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/analyst/tiago-fauth</loc>
  <lastmod>2024-01-17T09:45:50-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/analyst/cory-kasimov</loc>
  <lastmod>2024-05-23T16:19:39-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/analyst/biren-amin</loc>
  <lastmod>2024-09-05T09:50:32-04:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/analyst/rachel-elfman</loc>
  <lastmod>2025-02-12T16:41:17-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/analyst/trevor-allred</loc>
  <lastmod>2025-02-12T16:42:23-05:00</lastmod>
  <priority>0.5</priority>
 </url>
 <url>
  <loc>https://investor.bridgebio.com/analyst/greg-harrison</loc>
  <lastmod>2025-02-12T16:43:42-05:00</lastmod>
  <priority>0.5</priority>
 </url>
</urlset>
